1. pregnant or lactating females 2. critically ill with presence of one or more of the following signs: 1. difficulty breathing or shortness of breath 2. need for admission to a hospital or an intensive care unit, 3. acute respiratory failure requiring intubation/mechanical ventilation, 4. signs of shock including hypotension 5. oxygen saturation \< 92 % 3. any clinically significant screening laboratory results that are greater than 5 times the upper limit of normal. 4. estimated gfr \< 50 ml/min/1.73 m2 (calculated using either modification of diet in renal disease (mdrd) or cockcroft gualt 5. known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia 6. hemoglobin less than 10 gm/dl or hematocrit \< 30 % 7. retinal eye disease 8. known chronic kidney disease, stage - 5 or receiving dialysis 9. inability to tolerate oral medications 10. allergy or prior adverse reaction to either ribavirin or nitazoxanide 11. qtc interval \> 450 msec for men and women 12. history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval 13. current treatment with histamine-2 receptor antagonists (h2 blockers) and/or protein pump inhibitors and throughout the study. 14. have been vaccinated against covid-19 15. have participated in a clinical study in the past 30 days 16. any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that in the investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study

1. pregnant or lactating females 2. critically ill with presence of one or more of the following signs: 1. difficulty breathing or shortness of breath 2. need for admission to a hospital or an intensive care unit, 3. acute respiratory failure requiring intubation/mechanical ventilation, 4. signs of shock including hypotension 5. oxygen saturation \< 92 % 3. any clinically significant screening laboratory results that are greater than 5 times the upper limit of normal. 4. estimated gfr \< 50 ml/min/1.73 m2 (calculated using either modification of diet in renal disease (mdrd) or cockcroft gualt 5. known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia 6. hemoglobin less than 10 gm/dl or hematocrit \< 30 % 7. retinal eye disease 8. known chronic kidney disease, stage - 5 or receiving dialysis 9. inability to tolerate oral medications 10. allergy or prior adverse reaction to either ribavirin or nitazoxanide 11. qtc interval \> 450 msec for men and women 12. history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval 13. current treatment with histamine-2 receptor antagonists (h2 blockers) and/or protein pump inhibitors and throughout the study. 14. have been vaccinated against covid-19 15. have participated in a clinical study in the past 30 days 16. any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that in the investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study

pregnant or lactating females critically ill with presence of one or more of the following signs: difficulty breathing or shortness of breath need for admission to a hospital or an intensive care unit, acute respiratory failure requiring intubation/mechanical ventilation, signs of shock including hypotension oxygen saturation < 92 % any clinically significant screening laboratory results that are greater than 5 times the upper limit of normal. estimated gfr < 50 ml/min/1.73 m2 (calculated using either modification of diet in renal disease (mdrd) or cockcroft gualt known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia hemoglobin less than 10 gm/dl or hematocrit < 30 % retinal eye disease known chronic kidney disease, stage - 5 or receiving dialysis inability to tolerate oral medications allergy or prior adverse reaction to either ribavirin or nitazoxanide qtc interval > 450 msec for men and women history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval current treatment with histamine-2 receptor antagonists (h2 blockers) and/or protein pump inhibitors and throughout the study. have been vaccinated against covid-19 have participated in a clinical study in the past 30 days any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that in the investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study

pregnant or lactating females critically ill with presence of one or more of the following signs: difficulty breathing or shortness of breath need for admission to a hospital or an intensive care unit, acute respiratory failure requiring intubation/mechanical ventilation, signs of shock including hypotension oxygen saturation < 92 % any clinically significant screening laboratory results that are greater than 5 times the upper limit of normal. estimated gfr < 50 ml/min/1.73 m2 (calculated using either modification of diet in renal disease (mdrd) or cockcroft gualt known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia hemoglobin less than 10 gm/dl or hematocrit < 30 % retinal eye disease known chronic kidney disease, stage - 5 or receiving dialysis inability to tolerate oral medications allergy or prior adverse reaction to either ribavirin or nitazoxanide qtc interval > 450 msec for men and women history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval current treatment with histamine-2 receptor antagonists (h2 blockers) and/or protein pump inhibitors and throughout the study. have been vaccinated against covid-19 have participated in a clinical study in the past 30 days any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that in the investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study

1. pregnant or lactating females 2. critically ill with presence of one or more of the following signs: 1. difficulty breathing or shortness of breath 2. need for admission to a hospital or an intensive care unit, 3. acute respiratory failure requiring intubation/mechanical ventilation, 4. signs of shock including hypotension 5. oxygen saturation < 92 % 3. any clinically significant screening laboratory results that are greater than 5 times the upper limit of normal. 4. estimated gfr < 50 ml/min/1.73 m2 (calculated using either modification of diet in renal disease (mdrd) or cockcroft gualt 5. known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia 6. hemoglobin less than 10 gm/dl or hematocrit < 30 % 7. retinal eye disease 8. known chronic kidney disease, stage - 5 or receiving dialysis 9. inability to tolerate oral medications 10. allergy or prior adverse reaction to either ribavirin or nitazoxanide 11. qtc interval > 450 msec for men and women 12. history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval 13. current treatment with histamine-2 receptor antagonists (h2 blockers) and/or protein pump inhibitors and throughout the study. 14. have been vaccinated against covid-19 15. have participated in a clinical study in the past 30 days 16. any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that in the investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study

1. pregnant or lactating females 2. critically ill with presence of one or more of the following signs: 1. difficulty breathing or shortness of breath 2. need for admission to a hospital or an intensive care unit, 3. acute respiratory failure requiring intubation/mechanical ventilation, 4. signs of shock including hypotension 5. oxygen saturation < 92 % 3. any clinically significant screening laboratory results that are greater than 5 times the upper limit of normal. 4. estimated gfr < 50 ml/min/1.73 m2 (calculated using either modification of diet in renal disease (mdrd) or cockcroft gualt 5. known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia 6. hemoglobin less than 10 gm/dl or hematocrit < 30 % 7. retinal eye disease 8. known chronic kidney disease, stage - 5 or receiving dialysis 9. inability to tolerate oral medications 10. allergy or prior adverse reaction to either ribavirin or nitazoxanide 11. qtc interval > 450 msec for men and women 12. history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval 13. current treatment with histamine-2 receptor antagonists (h2 blockers) and/or protein pump inhibitors and throughout the study. 14. have been vaccinated against covid-19 15. have participated in a clinical study in the past 30 days 16. any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that in the investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study

1. critically ill with presence of one or more of the following signs: 1. difficulty breathing or shortness of breath 2. need for admission to a hospital or an intensive care unit, 3. acute respiratory failure requiring intubation/mechanical ventilation, 4. signs of shock including hypotension 5. oxygen saturation < 92 % 2. any clinically significant screening laboratory results that are greater than 5 times the upper limit of normal. 3. estimated gfr < 50 ml/min/1.73 m2 (calculated using either modification of diet in renal disease (mdrd) or cockcroft gualt 4. known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia 5. hemoglobin less than 10 gm/dl or hematocrit < 30 % 6. retinal eye disease 7. known chronic kidney disease, stage - 5 or receiving dialysis 8. inability to tolerate oral medications 9. allergy or prior adverse reaction to either ribavirin or nitazoxanide 10. qtc interval > 450 msec for men and women 11. history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval 12. current treatment with histamine-2 receptor antagonists (h2 blockers) and/or protein pump inhibitors and throughout the study. 13. any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that in the investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study

1. critically ill with presence of one or more of the following signs: 1. difficulty breathing or shortness of breath 2. need for admission to a hospital or an intensive care unit, 3. acute respiratory failure requiring intubation/mechanical ventilation, 4. signs of shock including hypotension 5. oxygen saturation < 92 % 2. any clinically significant screening laboratory results that are greater than 5 times the upper limit of normal. 3. estimated gfr < 50 ml/min/1.73 m2 (calculated using either modification of diet in renal disease (mdrd) or cockcroft gualt 4. known genetic hemoglobinopathy (e.g., thalassemia major or sickle cell anemia) or autoimmune hemolytic anemia 5. hemoglobin less than 10 gm/dl or hematocrit < 30 % 6. retinal eye disease 7. known chronic kidney disease, stage - 5 or receiving dialysis 8. inability to tolerate oral medications 9. allergy or prior adverse reaction to either ribavirin or nitazoxanide 10. qtc interval > 450 msec for men and women 11. history of torsade de pointes vt or prior cardiac arrest or congenital long qt interval 12. current treatment with histamine-2 receptor antagonists (h2 blockers) and/or protein pump inhibitors and throughout the study. 13. any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that in the investigator's judgment might interfere with study procedures or the ability of the subject to adhere to and complete the study